Pembrolizumab versus placebo as adjuvant therapy in resected high -risk stage II melanoma: Phase 3 KEYNOTE-716 study.

被引：2
|
作者：
Carlino, Matteo S.
Ascierto, Paolo Antonio
Eggermont, Alexander M.
Gershenwald, Jeffrey E.
Grob, Jean Jacques
Hauschild, Axel
Kirkwood, John M.
Long, Georgina V.
Mohr, Peter
Robert, Caroline
Ross, Merrick I.
Scolyer, Richard A.
Sondak, Vernon K.
Yoon, Charles
Poklepovic, Andrew Stewart
Rutkowski, Piotr
Anderson, James R.
Ahsan, Sama
Ibrahim, Nageatte
Luke, Jason J.
机构：
[1] Univ Sydney, Westmead Hosp, Sydney, NSW, Australia
[2] Univ Sydney, Blacktown Hosp, Melanoma Inst Australia, Sydney, NSW, Australia
[3] Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy
[4] Gustave Roussy Canc Ctr, Paris, France
[5] Univ Paris Saclay, Paris, France
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[7] Aix Marseille Univ, Marseille, France
[8] Univ Hautklin Kiel, Kiel, Germany
[9] Univ Pittsburgh, UPMC Hillman Canc Ctr, Melanoma Program, Pittsburgh, PA USA
[10] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia
[11] Royal North Shore Hosp, Sydney, NSW, Australia
[12] Mater Hosp, Sydney, NSW, Australia
[13] Elbe Kliniken Buxtehude, Buxtehude, Germany
[14] Gustave Roussy, Villejuif, France
[15] Paris Sud Univ, Villejuif, France
[16] Royal Prince Alfred Hosp, Sydney, NSW, Australia
[17] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[18] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[19] Dana Farber Canc Inst, Boston, MA 02115 USA
[20] VCU Massey Canc Ctr, Richmond, VA USA
[21] Maria Sklodowska Curie Inst, Warsaw, Poland
[22] Merck & Co Inc, Kenilworth, NJ USA
[23] Univ Chicago, Ctr Comprehens Canc, Chicago, IL 60637 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.TPS9596
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9596
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A randomized, double-blind, placebo-controlled phase II study of adjuvant pembrolizumab versus placebo in patients with head and neck squamous cell cancers at high risk for recurrence: The PATHWay study.
    Pearson, Alexander T.
    Seiwert, Tanguy Y.
    Cohen, Roger B.
    Saba, Nabil F.
    Kaczmar, John M.
    Fidler, Mary J.
    Wade, James L., III
    Castellucci, Enrico
    Karrison, Theodore
    Katipally, Rohan Reddy
    Juloori, Aditya
    Rosenberg, Ari Joseph
    Haraf, Daniel J.
    Agrawal, Nishant
    Vokes, Everett E.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] INTerpath-001: Pembrolizumab with V940 (mRNA-4157) versus pembrolizumab with placebo for adjuvant treatment of high-risk stage II-IV melanoma
    Weber, Jeffrey S.
    Luke, Jason J.
    Carlino, Matteo S.
    Khattak, Muhammad Adnan
    Meehan, Robert S.
    Brown, Michelle
    Zhang, Jinchun
    Krepler, Clemens
    Duic, J. Paul
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study.
    Choueiri, Toni K.
    Tomczak, Piotr
    Park, Se Hoon
    Venugopal, Balaji
    Ferguson, Tom
    Chang, Yen-Hwa
    Hajek, Jaroslav
    Symeonides, Stefan N.
    Lee, Jae-Lyun
    Sarwar, Naveed
    Thiery-Vuillemin, Antoine
    Gross-Goupil, Marine
    Mahave, Mauricio
    Haas, Naomi B.
    Sawrycki, Piotr
    Zhang, Eric
    Rogerio, Jaqueline Willemann
    Imai, Kentaro
    Quinn, David I.
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (18)
  • [34] A phase II study of neoadjuvant pembrolizumab and lenvatinib for resectable stage III melanoma: The neopele study.
    Gonzalez, Maria
    Menzies, Alexander M.
    Pennington, Thomas
    Saw, Robyn P. M.
    Spillane, Andrew J.
    Stretch, Jonathan
    Shannon, Kerwin Frank
    Ch'ng, Sydney
    Nieweg, Omgo E.
    Rojas, Maria Cruzado
    Osorio, Monica
    Rawson, Robert, V
    Ferguson, Peter M.
    Rizos, Helen
    Lo, Serigne
    Scolyer, Richard A.
    Long, Georgina, V
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [35] Utilization and survival benefit of adjuvant immunotherapy in resected high-risk stage II melanoma
    Wong, William G.
    Holguin, Rolfy A. Perez
    Stahl, Kelly A.
    Olecki, Elizabeth J.
    Pameijer, Colette
    Shen, Chan
    SURGERY IN PRACTICE AND SCIENCE, 2022, 8
  • [36] Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial
    Eggermont, Alexander M. M.
    Kicinski, Michal
    Blank, Christian U.
    Mandala, Mario
    V. Long, Georgina
    Atkinson, Victoria
    Dalle, Stephane
    Haydon, Andrew
    Meshcheryakov, Andrey
    Khattak, Adnan
    Carlino, Matteo S.
    Sandhu, Shahneen
    Larkin, James
    Puig, Susana
    Ascierto, Paolo A.
    Rutkowski, Piotr
    Schadendorf, Dirk
    Boers-Sonderen, Marye
    Di Giacomo, Anna Maria
    van den Eertwegh, Alfonsus J. M.
    Grob, Jean-Jacques
    Gutzmer, Ralf
    Jamal, Rahima
    van Akkooi, Alexander C. J.
    Lorigan, Paul
    Grebennik, Dmitri
    Kreplere, Clemens
    Marreaud, Sandrine
    Suciu, Stefan
    Robert, Caroline
    EUROPEAN JOURNAL OF CANCER, 2024, 211
  • [37] Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma*
    Kennedy, Oliver John
    Glassee, Nina
    Kicinski, Michal
    Blank, Christian U.
    V. Long, Georgina
    Atkinson, Victoria G.
    Dalle, Stephane
    Haydon, Andrew M.
    Meshcheryakov, Andrey
    Khattak, Adnan
    Carlino, Matteo S.
    Sandhu, Shahneen
    Larkin, James
    Puig, Susana
    Ascierto, Paolo A.
    Rutkowski, Piotr
    Schadendorf, Dirk
    Boers-Sonderen, Marye
    Giacomo, Anna Maria Di
    Eertwegh, Alfonsus J. M. van den
    Grob, Jean -Jacques
    Gutzmer, Ralf
    Jamal, Rahima
    Akkooi, Alexander C. J. van
    Gandini, Sara
    Buhrer, Emanuel
    Suciu, Stefan
    Robert, Caroline
    Eggermont, Alexander M. M.
    Mandala, Mario
    Lorigan, Paul
    Valpione, Sara
    EUROPEAN JOURNAL OF CANCER, 2024, 201
  • [38] Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States
    Bensimon, Arielle G.
    Zhou, Zheng-Yi
    Jenkins, Madeline
    Song, Yan
    Gao, Wei
    Signorovitch, James
    Krepler, Clemens
    Liu, Frank Xiaoqing
    Wang, Jingshu
    Aguiar-Ibanez, Raquel
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (10) : 981 - 993
  • [39] Adjuvant Therapy With Nivolumab Versus Placebo in Patients With Resected Stage IIB/C Melanoma (Checkmate 76K)
    Gastman, Brian
    Long, Georgina V.
    Kirkwood, John M.
    Hoeller, Christoph
    Weber, Jeffrey
    Grob, Jean-Jacques
    Mohr, Peter
    Grabbe, Stephan
    Dutriaux, Caroline
    Chiarion-Sileni, Vanna
    Mackiewicz, Jacek
    Rutkowski, Piotr
    Arenberger, Petr
    Quereux, Gaelle
    Meniawy, Tarek
    Ascierto, Paolo A.
    van Akkooi, Alexander
    Durani, Piyush
    Campigotto, Federico
    Del Vecchio, Michele
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 1) : S35 - S36
  • [40] Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study.
    Shah, Manish A.
    Adenis, Antoine
    Enzinger, Peter C.
    Kojima, Takashi
    Muro, Kei
    Bennouna, Jaafar
    Francois, Eric
    Hsu, Chih-Hung
    Moriwaki, Toshikazu
    Kim, Sung-Bae
    Lee, Se-Hoon
    Kato, Ken
    Shen, Lin
    Qin, Shukui
    Ferreira, Paula
    Wang, Ruixue
    Bhagia, Pooja
    Kang, S. Peter
    Metges, Jean-Philippe
    Doi, Toshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345